Lilly willing to cooperate with Korean scientists over MDR-TB programs

Published: 2008-04-14 06:54:00

Updated: 2008-04-14 06:54:00

Eli Lilly, a U.S.-based pharmaceutical company, plans to expand its research programs to fight multidrug-resistant tuberculosis (MDR-TB) with Korean scientists.

“We have talked with Korea’s research institutes including the Korea Advanced Institute of Science and Technology for the MDR-TB prog...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK